1995 To download high-resolution, print-ready JPEG images, click on the thumbnail image above. 2, 2001 New Study Shows Cialis Absorption Not Affected by Food Intake The first presentation of a large-scale integrated analysis of Phase III data on Cialis(TM) (tadalafil), a new oral treatment for erectile dysfunction (ED) being developed by Lilly ICOS LLC, shows a consistent response to the investigational treatment. These men included those who had a range of cialis tadalafil co-morbid conditions associated with ED, such as cardiovascular disease and diabetes mellitus. You can reach the story directly by going Cialis tadalafil to http://www. Newstream. Com/cgi-bin/display_story. Cgi?11473 This multimedia news story is cialis tadalafil for free and unrestricted use on your news information site (and for print or broadcast too). The results of these discussions will allow Lilly ICOS to provide a better estimate of the potential U. ED is a common complication of diabetes, affecting between 27 and 75 percent of men with the disease. (6) The World Health Organization estimates 151 million people worldwide have diabetes. (7) In the Phase III studies, participants were instructed to take study medication at the time of their choosing prior to sexual activity, with no more than one dose daily. During the 2003 third quarter, worldwide sales of Cialis totalled $50. 2 million, an increase of $12. 8 million over the sales reported during the second cialis tadalafil quarter. In the U. , an analysis of IMS data shows that Cialis is the number one PDE5 inhibitor for patients switching from one erectile dysfunction cialis tadalafil medication to another. " Recently, Lilly ICOS initiated a Phase 2 clinical study of tadalafil to treat patients with benign prostatic hyperplasia (BPH). A small number of men also reported abnormal vision. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and inflammatory cialis tadalafil diseases. Following the CPMP’s positive opinion, the application will be reviewed by the European Commission, which has authority to grant marketing authorization for the European Union. In December 2002, it was announced that Pafase(R) failed to demonstrate clinical benefit cialis tadalafil in a Phase 3 study in severe sepsis. About Lilly ICOS LLC Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company, was formed to develop Cialis tadalafil and market Cialis. More specifically, there can be no assurance that this product will receive additional regulatory approvals as expected or achieve commercial success or that competing products will not pre-empt any market opportunity that might exist for the product. There were no treatment- emergent serious adverse cialis tadalafil events reported. We are delighted with the high physician and patient awareness of Cialis so soon after the cialis tadalafil product launch, stated ICOS Chairman and Chief Executive Officer, Paul Clark. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by management. Elsewhere, Lilly has rights to market Cialis, and pays a royalty, to Lilly ICOS, equal to 20% of net product sales in those territories. Cialis should not be used by those who are being treated with nitrates such as nitroglycerin tablets or patches.